BLSM
BlossomHill Therapeutics, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
-20/100
Last price
17.29
▼ 2.65 (13.29%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
19.94
Day high
20.06
Day low
17.06
Volume
247.36K
Market cap
$549.56M
P/E (TTM)
—
52W range
15.25 – 27.99
Trailing performance
Returnvs SPY
1W
-19.09%
-21.0%
1M
-21.44%
-22.6%
3M
—
-4.5%
6M
—
-18.2%
YTD
+8.06%
-6.2%
1Y
—
-16.4%
3Y
—
-82.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on BLSM open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
4.04M
Total on file
Fundamentals
Market cap$549.56M
Enterprise value$734.38M
Revenue (TTM)—
Gross profit—
EBITDA$-84.74M
Net income$-81.60M
EPS (TTM)$-4.70
Free cash flow—
Total cash$95.38M
Total debt$23.37M
Book value / share$-63.15
Shares outstanding31.78M
Float17.74M
Short % of float—
Dividend yield0.00%
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E-4.37
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA-8.67
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity—
Return on assets—
Debt / equity28.49
Current ratio5.42
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Total revenue | $0 | $0 | — |
| Operating revenue | $0 | $0 | — |
| Research & development | $56.14M | $31.81M | +76.5% |
| Selling, general & admin | $7.89M | $4.59M | +71.8% |
| Total operating expense | $64.02M | $36.40M | +75.9% |
| Operating income | -$64.02M | -$36.40M | -75.9% |
| Net interest income | $3.48M | $5.71M | -39.0% |
| Pre-tax income | -$60.55M | -$30.70M | -97.3% |
| Net income | -$60.55M | -$30.70M | -97.3% |
| Net income to common | -$60.55M | -$30.70M | -97.3% |
| Basic EPS | -3.69 | -1.47 | -150.5% |
| Diluted EPS | -3.69 | -1.47 | -150.5% |
| EBIT | -$64.02M | -$36.40M | -75.9% |
| EBITDA | -$63.58M | -$36.05M | -76.4% |
| Basic shares | 16.41M | 20.84M | -21.3% |
| Diluted shares | 16.41M | 30.64M | -46.5% |
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Cash & equivalents | $136.68M | $100.15M | +36.5% |
| Cash & short-term investments | $136.68M | $100.15M | +36.5% |
| Total current assets | $138.83M | $104.17M | +33.3% |
| Property, plant & equipment | $21.56M | $1.50M | +1,340.1% |
| Goodwill & intangibles | $89.00K | $89.00K | 0.0% |
| Total assets | $162.97M | $106.78M | +52.6% |
| Total current liabilities | $15.48M | $6.77M | +128.6% |
| Total debt | $22.40M | $525.00K | +4,166.3% |
| Total liabilities | $294.70M | $179.66M | +64.0% |
| Retained earnings | -$135.03M | -$74.47M | -81.3% |
| Shareholder equity | -$131.73M | -$72.88M | -80.7% |
| Working capital | $123.35M | $97.40M | +26.6% |
| Net tangible assets | -$131.82M | -$72.97M | -80.6% |
| Shares issued | 30.64M | 30.64M | 0.0% |
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Net income | -$60.55M | -$30.70M | -97.3% |
| Depreciation & amortisation | $441.00K | $350.00K | +26.0% |
| Stock-based compensation | $1.09M | $504.00K | +116.3% |
| Change in working capital | $10.81M | -$2.27M | +575.8% |
| Operating cash flow | -$46.92M | -$31.42M | -49.4% |
| Capital expenditure | -$1.07M | -$92.00K | -1,059.8% |
| Investing cash flow | -$1.07M | -$92.00K | -1,059.8% |
| Financing cash flow | $84.53M | $17.56M | +381.4% |
| Free cash flow | -$47.99M | -$31.51M | -52.3% |
| End cash position | $136.68M | $100.15M | +36.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $21.36M | $19.90M | $12.53M | $9.57M | +7.3% |
| Selling, general & admin | $3.31M | $2.21M | $1.57M | $1.88M | +50.3% |
| Total operating expense | $24.67M | $22.11M | $14.10M | $11.45M | +11.6% |
| Operating income | -$24.67M | -$22.11M | -$14.10M | -$11.45M | -11.6% |
| Net interest income | $915.00K | $1.10M | $859.00K | $976.00K | -17.0% |
| Pre-tax income | -$23.76M | -$21.01M | -$13.24M | -$10.48M | -13.1% |
| Net income | -$23.76M | -$21.01M | -$13.24M | -$10.48M | -13.1% |
| Net income to common | -$23.76M | -$21.01M | -$13.24M | -$10.48M | -13.1% |
| Basic EPS | -0.78 | -1.01 | -0.64 | -0.50 | +23.2% |
| Diluted EPS | -0.78 | -1.01 | -0.64 | -0.50 | +23.2% |
| EBIT | -$24.67M | -$22.11M | -$14.10M | -$11.45M | -11.6% |
| EBITDA | -$24.55M | -$21.98M | -$14.00M | -$11.37M | -11.7% |
| Basic shares | 29.08M | 20.84M | 20.84M | 20.84M | +39.6% |
| Diluted shares | 29.08M | 20.84M | 30.64M | 30.64M | +39.6% |
| Line item | 2026-06-30 | 2026-03-31 | YoY |
|---|---|---|---|
| Cash & equivalents | $95.38M | $116.00M | -17.8% |
| Cash & short-term investments | $95.38M | $116.00M | -17.8% |
| Total current assets | $100.97M | $119.72M | -15.7% |
| Property, plant & equipment | $20.69M | $21.21M | -2.5% |
| Total assets | $124.13M | $143.41M | -13.4% |
| Total current liabilities | $18.62M | $16.18M | +15.1% |
| Total debt | $23.37M | $23.02M | +1.5% |
| Total liabilities | $298.91M | $295.53M | +1.1% |
| Retained earnings | -$179.79M | -$156.04M | -15.2% |
| Shareholder equity | -$174.78M | -$152.12M | -14.9% |
| Working capital | $82.35M | $103.55M | -20.5% |
| Net tangible assets | -$174.78M | -$152.12M | -14.9% |
| Shares issued | 30.64M | 30.64M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|
| Net income | -$23.76M | -$21.01M | -$13.24M | -$10.48M | -13.1% |
| Depreciation & amortisation | $125.00K | $125.00K | $102.00K | $85.00K | 0.0% |
| Stock-based compensation | $577.00K | $323.00K | $254.00K | $231.00K | +78.6% |
| Change in working capital | -$577.00K | -$705.00K | $3.44M | -$996.00K | +18.2% |
| Operating cash flow | -$23.23M | -$20.94M | -$9.14M | -$10.98M | -11.0% |
| Capital expenditure | — | -$13.00K | -$595.00K | -$402.00K | — |
| Investing cash flow | $0 | -$13.00K | -$595.00K | -$402.00K | +100.0% |
| Financing cash flow | $2.61M | $274.00K | $46.00K | $39.00K | +851.5% |
| Free cash flow | -$23.23M | -$20.95M | -$9.74M | -$11.38M | -10.9% |
| End cash position | $95.38M | $116.00M | $79.11M | $88.81M | -17.8% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.77 | -8.75 | -1,036.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.90 | 2 | $0 | — |
| Next quarter | -1.01 | 2 | $0 | — |
| Current year | -5.10 | 2 | $0 | — |
| Next year | -3.95 | 2 | $0 | 0.0% |
Analyst targets & ownership
Mean target$35.40
High target$40.00
Low target$30.00
Implied upside104.74%
Analyst count5
ConsensusSTRONG BUY
Strong buy / Buy1 / 4
Hold0
Sell / Strong sell0 / 0
Held by insiders12.71%
Held by institutions30.56%
Institutions holding10
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
19.94
-13.30% from price
SMA 20
21.93
-21.15% from price
SMA 50
—
—
SMA 100
—
—
SMA 200
—
—
EMA 12
20.27
-14.70% from price
EMA 26
20.33
-14.97% from price
EMA 50
—
—
RSI (14)
39.5
Neutral
MACD (12,26,9)
-0.06
Hist -0.87
ATR (14)
2.25
12.99% of price
Realised vol 30D
114.3%
Annualised
Bollinger upper
27.47
20, 2σ
Bollinger lower
16.39
20, 2σ
50 / 200 cross
—
—
Trend bias
—
—
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
—
—
Correlation to SPY
—
—
Realised vol 30D
114.3%
Annualised
Market vol 1Y
—
SPY, annualised
Max drawdown 1Y
-35.5%
Peak to trough
Max drawdown 5Y
-35.5%
Peak to trough
ATR 14
2.25
12.99% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
137.57K
Prior 111.89K
Change vs prior
+22.9%
Shorts adding
% of float
—
—
% of shares out
0.45%
Against total outstanding
Days to cover
0.9
Liquid
Float
17.74M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 21, 26 | Leerink Partners | MAINTAINED | Outperform | Outperform |
| Sep 21, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Sep 1, 26 | LifeSci Capital | INITIATED | — | Outperform |
| Sep 1, 26 | Leerink Partners | INITIATED | — | Outperform |
| Sep 1, 26 | JP Morgan | INITIATED | — | Overweight |
| Sep 1, 26 | Guggenheim | INITIATED | — | Buy |
| Sep 1, 26 | HC Wainwright & Co. | INITIATED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Periodic Financial Reports
10-Q · 2026-09-18
Corporate Changes & Voting Matters
8-K · 2026-09-15
Offering Registrations
S-8 · 2026-08-10
Offering Registrations
S-1MEF · 2026-08-06
Trading Registrations
8-A12B · 2026-08-04
Offering Registrations
S-1/A · 2026-08-03
Offering Registrations
S-1 · 2026-07-17
Offering Registrations
DRS/A · 2026-06-11
Headlines
BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer
GlobeNewswire · 9d ago
BlossomHill Therapeutics Q2 Loss Widens
MT Newswires · 19d ago
BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
GlobeNewswire · 19d ago
BlossomHill Therapeutics Shares Rise 4.4% After BH-30643 Trial Update
InvestorsHub · 22d ago
BlossomHill Drug Shows 45% Response Rate in Lung Cancer Trial
MT Newswires · 22d ago
BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer
GlobeNewswire · 22d ago
BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · 34d ago
BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer
GlobeNewswire · 36d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.